These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31383016)

  • 1. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
    Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
    J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
    Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
    J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy.
    Liu S; Zhang Y; Lin Y; Wang P; Pan Y
    Front Immunol; 2022; 13():981527. PubMed ID: 36119063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report.
    He Y; Wang L; Li X; Zhang T; Song T; Zhang J; Yu Y; Chen S; Song H
    Front Oncol; 2021; 11():596342. PubMed ID: 34113555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report.
    Zhang F; Zhang J; Zhao L; Zhai M; Zhang T; Yu D
    Front Immunol; 2021; 12():759250. PubMed ID: 34950137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.
    Zhong L; Liu X; Li Z; Zhang X; Wang Y; Peng W
    Front Oncol; 2021; 11():783158. PubMed ID: 35096582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
    Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
    BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
    Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
    Front Immunol; 2021; 12():744571. PubMed ID: 34603331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.
    Liu Y; Du J; Zhang P; Meng W; Xiao H
    Front Oncol; 2023; 13():1051786. PubMed ID: 36969074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
    Dong Z; Liao B; Shen W; Sui C; Yang J
    Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review.
    Zhang J; Wu L; Liu J; Lin M
    Immunotherapy; 2020 Jun; 12(8):555-561. PubMed ID: 32372672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.